Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Conditions: Cutaneous Squamous Cell Carcinoma

First Posted Date: 2018-04-10

Last Posted Date: 2019-08-01

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT03492489

To Assess the Patients' Ability to Self-Administer Fasinumab

Phase 1

Completed

Conditions: Osteoarthritis, Hip
Osteoarthritis, Knee

Interventions: Drug: Fasinumab AI
Drug: Fasinumab PFS

First Posted Date: 2018-04-09

Last Posted Date: 2021-03-03

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT03491904

Locations: 🇺🇸
Regeneron Research Facility, Houston, Texas, United States

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Phase 2

Completed

Conditions: Severe Hypertriglyceridemia (sHTG)

Interventions: Drug: Placebo
Drug: evinacumab

First Posted Date: 2018-03-02

Last Posted Date: 2023-02-16

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT03452228

Locations: 🇬🇧
Regeneron Research Facility, Manchester, United Kingdom

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: CMP-001
Drug: Atezolizumab
Radiation: Radiation Therapy

First Posted Date: 2018-02-19

Last Posted Date: 2022-08-03

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT03438318

Locations: 🇺🇸
University of Colorado Aurora, Aurora, Colorado, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 2 locations

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Phase 2

Terminated

Conditions: Advanced Non-Small Cell Lung Carcinoma

Interventions: Drug: SDREGN2810
Drug: SDREGN2810/ipi
Drug: HDREGN2810

First Posted Date: 2018-02-12

Last Posted Date: 2022-11-03

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT03430063

Locations: 🇬🇧
Regeneron Research Site, Plymouth, United Kingdom

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Active, not recruiting

Conditions: Dermatitis, Atopic

First Posted Date: 2018-02-09

Last Posted Date: 2025-01-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 858

Registration Number: NCT03428646

Locations: 🇨🇦
Regeneron Investigational Site, Quebec, Canada

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Phase 3

Completed

Conditions: Homozygous Familial Hypercholesterolemia

Interventions: Drug: evinacumab

First Posted Date: 2018-01-24

Last Posted Date: 2025-04-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT03409744

Locations: 🇺🇦
Clinical Trial Site #2, Kharkiv, Ukraine
🇺🇦
Clinical Trial Site, Kyiv, Ukraine
🇿🇦
Regeneron Study Site, Cape Town, Western Cape, South Africa

and more 2 locations

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: REGN2810
Other: Chemotherapy
Drug: REGN2810/chemo/ipi

First Posted Date: 2018-01-24

Last Posted Date: 2025-03-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 790

Registration Number: NCT03409614

Locations: 🇹🇭
Regeneron Research Site #2, Ratchathewi, Bangkok, Thailand
🇺🇦
Regeneron Research Site, Vinnytsia, Ukraine
🇹🇭
Regeneron Research Site #1, Ratchathewi, Thailand

and more 1 locations